Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Haoshen FengYabin ZhaoZhenhua LiJian KangPublished in: Therapeutic advances in respiratory disease (2021)
Pirfenidone safely reduced disease progression by improving the lung function and progression-free survival in IPF patients, with acceptable side effects. The efficacy of pirfenidone on f-iNSIP was not significant, suggesting the need for further studies.The reviews of this paper are available via the supplemental material section.
Keyphrases
- idiopathic pulmonary fibrosis
- lung function
- free survival
- interstitial lung disease
- end stage renal disease
- cystic fibrosis
- ejection fraction
- chronic obstructive pulmonary disease
- chronic kidney disease
- newly diagnosed
- air pollution
- peritoneal dialysis
- mental health
- prognostic factors
- patient reported
- meta analyses
- case control